Brief: Krystal Biotech Receives European Commission Orphan Tag For Cystic Fibrosis Treatment
18/01/2023 13:56
Jan 18 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH RECEIVES EUROPEAN COMMISSION ORPHAN
DESIGNATION
FOR KB407 FOR THE TREATMENT OF CYSTIC FIBROSIS
* KRYSTAL BIOTECH INC - U.S. FOOD AND DRUG ADMINISTRATION
HAS ALSO
GRANTED ORPHAN DRUG DESIGNATION FOR KB407 TO TREAT PATIENTS WITH
CF
Source text for Eikon: ID:nGNX3D28xX
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion